Merck & Co (NY:MRK)

144.30 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

99 100 Next >

The New Era of Johnson & Johnson: A 2026 Deep-Dive Research Feature

January 19, 2026

As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its...

Via Finterra

3 Profitable Stocks to Consider Right Now

January 18, 2026

Profitable companies tend to be more resilient, giving them the flexibility to invest and return capital to shareholders. Businesses that consistently generate earnings can better navigate downturns...

Via StockStory

ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗

January 16, 2026

Via Stocktwits

Topics Intellectual Property

The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026

January 16, 2026

As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based...

Via Finterra

Topics Initial Public Offering Intellectual Property Lawsuit

Merck & Co. Inc. (NYSE:MRK) Presents a Compelling Value Investment Case ↗

January 14, 2026

Via Chartmill

January 15, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Via StockStory

The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape

January 15, 2026

As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic...

Via MarketMinute

Topics Economy Intellectual Property

Healthcare Titan Ascendant: Johnson & Johnson Hits All-Time Highs as It Navigates a New Political and Clinical Era

January 15, 2026

As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Earnings

Merck In Talks To Acquire Revolution Medicines For About $30B: Report ↗

January 09, 2026

Via Stocktwits

Merck Looks To Buy Cancer Drugmaker Revolution Medicines: Report ↗

January 08, 2026

Via Stocktwits

A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗

January 15, 2026

Via Chartmill

Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot

January 14, 2026

Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period...

Via Finterra

Topics Initial Public Offering Intellectual Property

The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape

January 12, 2026

As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the...

Via MarketMinute

Topics Economy Intellectual Property World Trade

Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B ↗

January 12, 2026

When asked about the company’s strategic transactions, CEO Mark Goldsmith said at a conference that the company has a policy of not commenting on rumors or speculation.

Via Stocktwits

The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance

January 12, 2026

The 44th Annual J.P. Morgan Healthcare Conference opened today in San Francisco with an intensity not seen in years, as the healthcare and technology sectors officially merged their futures. The...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

3 Dividend Stocks to Hold for the Next 10 Years ↗

January 12, 2026

All three companies are in better shape than most investors are (understandably) presuming.

Via The Motley Fool

Topics Bonds

1 Momentum Stock Worth Your Attention and 2 Facing Headwinds

January 11, 2026

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...

Via StockStory

This ETF Is Proof That the Healthcare Rebound Is Real ↗

January 11, 2026

Via MarketBeat

Topics ETFs

Why Revolution Medicines Stock Surged by 11% Today ↗

January 09, 2026

The company might become the latest biotech acquisition story soon.

Via The Motley Fool

Topics Intellectual Property

MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation

January 09, 2026

MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its...

Via MarketMinute

Topics Intellectual Property

Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics

January 09, 2026

Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the...

Via PredictStreet

Topics Initial Public Offering Intellectual Property

Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight ↗

January 09, 2026

Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32...

Via Benzinga

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗

January 08, 2026

Via Stocktwits

Topics Government

American Trade Resilience: Deficit Hits 17-Year Low as Export Surge and Tariff Shocks Reshape Global Commerce

January 08, 2026

In a landmark shift for the American economy, the U.S. trade deficit has plummeted to its lowest level in 17 years, signaling a profound transformation in global supply chains and domestic production....

Via MarketMinute

Topics Artificial Intelligence Economy Energy

The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader

January 08, 2026

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...

Via MarketMinute

Topics Intellectual Property

Neogen Shares Skyrocket as Q2 Earnings Beat Signals Turning Point in 3M Integration Strategy

January 08, 2026

LANSING, MI – Shares of Neogen Corporation (NASDAQ: NEOG) experienced a dramatic surge in early trading today, climbing nearly 29% after the food and animal safety leader reported second-quarter fiscal...

Via MarketMinute

Topics Earnings Economy

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era

January 07, 2026

As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands...

Via MarketMinute

Topics Economy

3 Drug Stocks to Buy at a Discount ↗

January 07, 2026

The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.

Via The Motley Fool

Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge

January 07, 2026

Date: January 7, 2026 Introduction Moderna, Inc. (NASDAQ: MRNA), once the definitive poster child of the COVID-19 pandemic response, is currently undergoing one of the most significant pivots in the...

Via PredictStreet

Topics Economy Initial Public Offering Intellectual Property

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.